Cas:906352-64-5 N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine manufacturer & supplier

Chemical Name:N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine

CAS.NO:906352-64-5

Synonyms:N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine

Molecular Formula:C₁₁H₁₄N₄

Molecular Weight:202.25600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:365ºC at 760 mmHg

Density:1.14g/cm3

Index of Refraction:1.607

PSA:42.74000

Exact Mass:202.12200

LogP:1.43670

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine Use and application,N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine technical grade,usp/ep/jp grade.

Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine manufacturer We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine supplier Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine vendor Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. N-methyl-1-[2-(1,2,4-triazol-1-ylmethyl)phenyl]methanamine factory The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study.